2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17383R
    Levomefolate calcium (Standard) 151533-22-1 98.97%
    Levomefolate calcium (Standard) is the analytical standard of Levomefolate calcium. This product is intended for research and analytical applications. Levomefolate calcium is a synthetic calcium salt of L-5-methyltetrahydrofolate and an orally active and brain-penetrant folate supplement. Levomefolate calcium incorporates into body folate pools to increase plasma and red blood cell folate levels over time. Levomefolate calcium does not significantly increase folate concentrations in breast milk. Levomefolate calcium can be used for the research of neural tube defects and megaloblastic anemia.
    Levomefolate calcium (Standard)
  • HY-174066
    SI-W052 2572552-60-2 98.0%
    SI-W052 is an orally active, brain-penetrant and selective small-molecule inhibitor targeting mTOR and TEX264. SI-W052 activates autophagy by inhibiting mTOR phosphorylation and enhances TEX264 expression to promote ER turnover, suppressing LPS-induced release of inflammatory factors (TNF-α, IL-6). SI-W052 is promising for research of Alzheimer’s disease (AD)-associated neuroinflammation.
    SI-W052
  • HY-174371
    INNO-220 3032576-92-1 98.60%
    INNO-220 is an orally active, CRBN-dependent molecular glue degrader targeting CK1α. INNO-220 induces cell cycle arrest at G0/G1 phase and triggers apoptosis by degrading CK1α. INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, thereby inhibiting NF-κB signaling in stimulated T cells and lymphoma cells that harbor an activating mutation in CARD11. INNO-220 provides a new direction for lymphoma research.
    INNO-220
  • HY-175278
    BAL-1516 98%
    BAL-1516 is an orally active NLRP3 inhibitor with human NLRP3 Kd of 14.2 nM, mouse NLRP3 Kd of 200 nM, and blood-brain barrier penetration.BAL-1516 binds to a surface groove of the NLRP3 nucleotide-binding domain, contacts FISNA and WHD subdomains, forms three hydrogen bonds to the peripheral β-strand of the triple-ATPase, and does not alter NLRP3 ATP-hydrolysis activity.BAL-1516 shows specificity for NLRP3 over other NOD-like receptors, directly binds mouse NLRP3, and inhibits inflammasome formation in monocytes and microglia.
    BAL-1516
  • HY-17541A
    Cysteine Protease inhibitor hydrochloride 2197053-49-7
    Cysteine Protease inhibitor hydrochloride, an inhibitor of Cysteine Protease, binds to acetylcholinesterase (AChE). Cysteine Protease inhibitor hydrochloride is applicable to the research of Alzheimer's disease.
    Cysteine Protease inhibitor hydrochloride
  • HY-175453
    MRT-23227 3050683-03-6 99.45%
    MRT-23227 is a molecular glue degrader that targets cereblon (CRBN). MRT-23227 forms a ternary complex with CRBN and G3BP2, activating the ubiquitin-proteasome system, leading to G3BP2 degradation. MRT-23227 has potential applications in the research of G3BP2-related cancers (such as breast and lung cancer) and neurodegenerative diseases.
    MRT-23227
  • HY-175840
    TAU-IN-5 3118812-61-3 99.12%
    TAU-IN-5 (compound 13) is a TAU protein inhibitor with an EC50 of 0.81 μM. TAU-IN-5 inhibits the formation of tau (2N4R isoform) oligomers and reduces the formation of tau dimers. TAU-IN-5 can be used in the study of Alzheimer's disease (AD) and Parkinson's disease (PD).
    TAU-IN-5
  • HY-176411
    ONO-TR-772 2640847-32-9 99.43%
    ONO-TR-772 (VU6018042) is a selective TREK inhibitor (IC50: 15 nM). ONO-TR-772 enhances recognition memory in the MK-801-stimulated NOR mouse model. ONO-TR-772 can be used in the study of diseases related to cognitive impairment.
    ONO-TR-772
  • HY-176434
    DDL-218 2767324-34-3 99.49%
    DDL-218 is an orally active and potent SirT1 inhibitor. DDL-218 enhances SirT1 in ApoE4-expressing neurons and a murine AD model. DDL-218 can be used in the study of Alzheimer's disease.
    DDL-218
  • HY-176518
    ssPalmE-P4-C2 2247153-41-7 98.81%
    ssPalmE-P4-C2 is a SS-cleavable and pH-sensitive lipid-like material (ssPalm) with a vitamin E‑scaffold. ssPalmE-P4-C2 improves gene knockdown activity against FVII with an ED50 of 0.5 mg/kg. ssPalmE-P4-C2 can be used to synthesize lipid nanoparticles (LNPs) for delivering siRNA to the hepatocyte. ssPalmE-P4-C2 can be used for the RNA therapies for dyslipidemia, hepatitis B/C infections and transthyretin amyloidosis research.
    ssPalmE-P4-C2
  • HY-176900
    GPR52 agonist-4 1313195-88-8 98.09%
    GPR52 agonist-4 (Compound 65) is a highly selective G-protein-coupled receptor GPR52 modulator. GPR52 agonist-4 is promising for research of neuropsychiatric diseases.
    GPR52 agonist-4
  • HY-177073
    Cleminorexton 2980518-93-0 98%
    Cleminorexton is an orally active orexin-2 receptor (OX2R) agonist with a pEC50 between 9 and 10.4. Cleminorexton can be used for narcolepsy and other conditions associated with orexin deficiency and/or excessive sleepiness.
    Cleminorexton
  • HY-177093
    Irafamdastat 2244136-58-9 98.07%
    Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC50s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect.
    Irafamdastat
  • HY-177906
    h-FTAA 1352477-26-9 98%
    h-FTAA is a luminescent conjugated oligothiophene (LCO) probe. h-FTAA can selectively bind to amyloid protein aggregates (such as Aβ plaques) and distinguish different conformations of the protein aggregates through changes in fluorescence signals. h-FTAA significantly reduces the neurotoxicity of Aβ1-42 and the Arctic mutant Aβ (AβArc), thereby protecting SH-SY5Y neuroblastoma cells. h-FTAA can be used to dynamically track the formation and maturation process of Aβ plaques.
    h-FTAA
  • HY-178121
    JNJ-78911118 3106013-91-3 99.38%
    JNJ-78911118 is a potent, brain-penetrant, selective GluN2A antagonist (IC50 = 44 nM). JNJ-78911118 shows >200-fold selectivity against GluN1/2B, 2C and 2D receptors. JNJ-78911118 functions as a negative allosteric modulator (NAM) by insurmountably suppressing glutamate efficacy and reducing glycine potency at GluN1/2A receptors. JNJ-78911118 produces profound pharmacodynamic effects in vivo. JNJ-78911118 can be used for depression research.
    JNJ-78911118
  • HY-178154
    FB231 2166045-37-8
    FB231 is a Parkin activator. FB231 can induce mild mitochondrial stress, resulting in impaired mitochondrial function and activation of the integrated stress response. FB231 can lower the threshold for mitochondrial toxins to induce PINK1/Parkin-mediated mitophagy. FB231 can cause activation of the integrated stress response (ISR) and perturbation to iron-dependent pathways. FB231 can be used for the research of neurological disease, such as Parkinson’s disease.
    FB231
  • HY-178259
    α2AR agonist 2 719277-27-7 99.46%
    α2AR agonist 2 is a selective α2B adrenergic receptor antagonist (IC50 = 1.2 µM). α2AR agonist 2 can be used for research on inflammatory pain and neuropathic pain.
    α2AR agonist 2
  • HY-178324
    T2M-010 364611-21-2
    T2M-010 is a potent, brain-penetrant TREM2 agonist (Kd = 0.83 μM). T2M-010 activates receptor-proximal signaling, inducing SYK phosphorylation in TREM2-expressing cells, and promotes microglial phagocytosis. T2M-010 can be used for the study of protective microglial responses relevant to Alzheimer’s disease (AD).
    T2M-010
  • HY-178494
    Nav1.7-IN-19 3097995-73-5 98.87%
    Nav1.7-IN-19 is a potent, selective and orally active Nav1.7 inhibitor with an IC50 of 0.49 μM. Nav1.7-IN-19 shows high selectivity for Nav1.7, with selectivities of 312-fold and 662-fold against Nav1.1 and Nav1.5 in the inactivated state. Nav1.7-IN-19 exhibits weak inhibition on hERG potassium channels. Nav1.7-IN-19 exhibits analgesic effect and can be used for the research of neurological disease.
    Nav1.7-IN-19
  • HY-179573
    UCM-A86 1210899-51-6 98.64%
    UCM-A86 is a selective positive allosteric modulator of GluN1/GluN3 NMDA receptors with EC50 values of 21 µM and 19 µM at GluN1/GluN3A and GluN1/GluN3B receptors, respectively. UCM-A86 selectively potentiates responses from GluN1/GluN3A/B over GluN1/GluN2A-D receptors. UCM-A86 can be used in the research of central nervous system diseases.
    UCM-A86
Cat. No. Product Name / Synonyms Application Reactivity